Pfizer recently announced positive results from the BASIS study, the global phase 3 trial evaluating Hympavzi in young adults ...

Novo Nordisk's anti-TFPI antibody concizumab has been backed for approval in the EU as a once-daily drug to prevent bleeding episodes in people with haemophilia. The recommendation by the EMA's ...

The once-weekly anti-TFPI antibody has been cleared by the European Commission for adults and adolescents aged 123 and over with severe haemophilia A or B, without inhibitors, becoming the first ...

自2024年7月1日至2025年6月30日，多家国内上市公司有多个药物获批上市，按照药物类型分类，其中有约19个肿瘤药物、23个非肿瘤药物；以上药物后续有望参与2025年医保谈判。 【和黄医药】6月30日，和黄医药宣布其MET抑制剂赛沃替尼联合EGFR抑制剂奥希替尼疗法获NMPA批准上市，用于治疗EGFR-TKI耐药后伴MET扩增的晚期非鳞非小细胞肺癌。